Bioanalytical Method Development and Validation for the Determination of Favipiravir in Spiked Human Plasma by using RP-HPLC

被引:15
作者
Duse, Pallavi, V [1 ]
Baheti, Kamalkishor G. [2 ]
机构
[1] YB Chavan Coll Pharm, Aurangabad 431003, Maharashtra, India
[2] YB Chavan Coll Pharm, Dept Pharmaceut Chem, Aurangabad 431003, Maharashtra, India
关键词
Favipiravir; RP-HPLC; human plasma; validation; bioanalytical; method development;
D O I
10.9734/JPRI/2021/v33i47A33014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A precise, simple and reproducible reverse phase liquid chromatography (RP-HPLC) method was developed and validated for determination of Favipiravir by using Carbamazepine as internal standard in spiked human plasma. A chromatographic separation was accomplished with Cromasil C18 (250mm x 4.6ID, Particle size: 5 micron) column using mobile phase consists of methanol: water in the ratio (35:65, %v/v), at pH 3.0 with binary gradient system-maintained flow rate at 0.8ml/min. The detection wavelength of drug sample was at 225 nm. Extraction was done by using ethyl acetate as extracting solvent. The retention time of Favipiravir was found to be 6.62 min. The method was found to be linear in the concentration range of 0.2-3.2 mu g/ml. Limit of quantitation (LOQ) value was found to be 0.72. The intra- and inter day precision and accuracy lies within the specified range. The recovery studies were found to be in the range of 97.6 to 100.2%. %Relative standard deviation (RSD) was found to be in the range of 0.07-2.80%. All parameters were found to be validated from spiked human plasma. The proposed RP-HPLC method is highly accurate and rapid for the determination of favipiravir in human plasma and can be applied for pharmacokinetic studies and Therapeutic drug monitoring.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 15 条
[1]  
[Anonymous], 2015, China patent, Patent No. [CN104914185A), 104914185]
[2]  
[Anonymous], 2020, L570 QUANT AN FAV SP
[3]  
[Anonymous], 2016, China patent, Patent No. [CN104914185B, 104914185]
[4]   Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19 [J].
Casey, Jonathan D. ;
Johnson, Nicholas J. ;
Semler, Matthew W. ;
Collins, Sean P. ;
Aggarwal, Neil R. ;
Brower, Roy G. ;
Chang, Steven Y. ;
Eppensteiner, John ;
Filbin, Michael ;
Gibbs, Kevin W. ;
Ginde, Adit A. ;
Gong, Michelle N. ;
Harrell, Frank ;
Hayden, Douglas L. ;
Hough, Catherine L. ;
Khan, Akram ;
Leither, Lindsay M. ;
Moss, Marc ;
Oldmixon, Cathryn F. ;
Park, Pauline K. ;
Reineck, Lora A. ;
Ringwood, Nancy J. ;
Robinson, Bryce R. H. ;
Schoenfeld, David A. ;
Shapiro, Nathan, I ;
Steingrub, Jay S. ;
Torr, Donna K. ;
Weissman, Alexandra ;
Lindsell, Christopher J. ;
Rice, Todd W. ;
Thompson, B. Taylor ;
Brown, Samuel M. ;
Self, Wesley H. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (09) :1144-1153
[5]  
Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI 10.1101/2020.03.17.20037432
[6]  
Dominic F, 2020, LCMS/ MS analysis of small molecule antiviral and anti-inflammatory drugs in plasma in clinical research
[7]  
Egorova, 2020, CLIN INFECT DIS, V1176
[8]  
Eman, 2021, J PHARMACEUT BIOMED, V199
[9]   Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study [J].
Liu, Xi ;
Chen, Huili ;
Shang, Yuqi ;
Zhu, Hongqiong ;
Chen, Gongqi ;
Chen, Yuanli ;
Liu, Shaoxuan ;
Zhou, Yaoyong ;
Huang, Mingxing ;
Hong, Zhongsi ;
Xia, Jinyu .
TRIALS, 2020, 21 (01)
[10]   Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial [J].
Lou, Yan ;
Liu, Lin ;
Yao, Hangping ;
Hu, Xingjiang ;
Su, Junwei ;
Xu, Kaijin ;
Luo, Rui ;
Yang, Xi ;
He, Lingjuan ;
Lu, Xiaoyang ;
Zhao, Qingwei ;
Liang, Tingbo ;
Qiu, Yunqing .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157